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Low-order high-energy nifedipine (NIF) solid dispersions (SDs) were generated by melt solvent 
amorphization with polyethylene glycol (PEG) 1450 and hypromellose acetate succinate (HPMCAS-HF) to 
increase NIF solubility while achieving acceptable physical stability. HPMCAS-HF was used as a 
crystallization inhibitor. Individual formulation components, their physical mixtures (PMs), and SDs were 
characterized by differential scanning calorimetry, powder X-ray diffraction, and Fourier transform infrared 
spectroscopy (FTIR). NIF solubility and percent crystallinity (PC) were determined at the initial time and 
after 5 days stored at 25 °C and 60% RH. FTIR indicated that hydrogen bonding was involved with the 
amorphization process. FTIR showed that NIF:HPMCAS-HF intermolecular interactions were weaker than 
NIF:PEG 1450 interactions. NIF:PEG 1450 SD solubilities were significantly higher than their PM 
counterparts (p < 0.0001). The solubilities of NIF:PEG 1450:HPMCAS-HF SDs were significantly higher 
than their corresponding NIF:PEG 1450 SDs (p < 0.0001-0.043). All the SD solubilities showed a 
statistically significant decrease (p < 0.0001) after storage for 5 days. SDs PC were statistically lower 
than their comparable PMs (p < 0.0001). The PCs of SDs with HPMCAS-HF were significantly lower than 
SDs not containing only PEG 1450. All SDs exhibited a significant increase in PC (p < 0.0001–0.0089) on 
storage. Thermogravimetric analysis results showed that HPMCAS-HF bound water at higher 
temperatures than PEG 1450 (p < 0.0001–0.0039). HPMCAS-HF slowed the crystallization process of 
SDs, although it did not completely inhibit NIF crystal growth. 
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Abstract 
Low-order high-energy nifedipine (NIF) solid dispersions (SDs) were generated by melt solvent 
amorphization with PEG 1450 and HPMCAS-HF to increase NIF solubility while achieving 
acceptable physical stability. HPMCAS-HF was used as a crystallization inhibitor. Individual 
formulation components, their physical mixtures (PMs), and SDs were characterized by DSC, 
PXRD, and FTIR. NIF solubility and percent crystallinity (PC) were determined at initial time 
and after 5 days stored at 25 °C and 60% RH. FTIR indicated that hydrogen bonding was 
involved with the amorphization process. FTIR showed that NIF:HPMCAS-HF intermolecular 
interactions were weaker than NIF:PEG 1450 interactions. NIF:PEG 1450 SD solubilities were 
significantly higher than their PM counterparts (p<0.0001). The solubilities of NIF:PEG 
1450:HPMCAS-HF SDs were significantly higher than their corresponding NIF:PEG 1450 SDs 
(p<0.0001-0.043). All the SD solubilities showed a statistically significant decrease (p<0.0001) 
after storage for five days. SDs PC were statistically lower than their comparable PMs 
(p<0.0001). The PCs of SDs with HPMCAS-HF were significantly lower than SDs not 
containing only PEG 1450. All SDs exhibited a significant increase in PC (p<0.0001-0.0089) on 
storage. TGA results showed that HPMCAS-HF bound water at higher temperatures than PEG 
1450 (p<0.0001-0.0039). HPMCAS-HF slowed the crystallization process of SDs, although it 
did not completely inhibit NIF crystal growth. 
Key words 
Amorphization, DSC, FTIR, PXRD, melt solvent method, nifedipine, PEG 1450, HPMCAS-HF, 
solid dispersions, solubility  
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1. Introduction
Combinatorial chemistry and high throughput screening approaches have been widely used in the 
last two decades to identify potential new drug candidates. The majority of these candidates are 
either weak acids (a) or weak bases (b). In the expanded Biopharmaceutical Classification 
System (BCS), many of these candidates are identified as Class IIa and Class IIb compounds that 
have low solubility and high permeability (Tsume et al. 2014). A limited solubility of these Class 
II drugs impedes the oral bioavailability, and presents a key challenge in the development of 
novel drug candidates. Thus, the use of innovative technologies to improve drug solubility and 
dissolution rate has become an important product development strategy.  
Drug amorphization is a promising approach to improve the solubility and subsequent oral 
bioavailability of Class IIa and Class IIb drug candidates (Kesisoglou et al. 2007; Vasconcelos et 
al. 2007; Tsume et al. 2014). A solid dispersion (SD) is an important amorphization technique 
used to improve the drug solubility (Serajuddin 1999). Amorphous and low-ordered drug 
materials are higher energetic forms than their crystalline counterparts, which results in a higher 
apparent drug dissolution and solubility. These higher energy forms are also chemically and 
physically less stable than their crystalline counterparts. When drug amorphization technologies 
are used to increase drug solubility, the overarching product design goal is to create a higher 
energetic dosage form while ensuring product stability throughout its shelf life. Typically, 
amorphization is accomplished using a drug-polymer carrier system. These low-order materials 
exhibit greater molecular mobility. This increased mobility can accelerate the nucleation and 
crystallization process. Moisture present in the SD can also increase molecular mobility and 
support the drug nucleation process.  
Weakly acidic nifedipine (NIF) was chosen as a model Class IIa compound (Fig. 1) for 
amorphization studies. The aim of this investigation was to improve NIF’s solubility while 
minimizing drug re-crystallization. NIF SDs were prepared using polyethylene glycol (PEG) 
1450 with and without hypromellose acetate succinate (HPMCAS-HF). The working hypothesis 
states that intermolecular hydrogen bonding interactions between NIF and PEG 1450 in the 
presence of HPMCAS-HF would provide enhanced solubility and minimize recrystallization 
compared to a NIF:PEG 1450 SD alone. Kestuer and Taylor reported that strong and extensive 
hydrogen bonding between felodipine and povidone led to an effective inhibition of drug 
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 crystallization in the SDs (Kestur and Taylor 2010). PEG 1450 was also expected to function as 
a cosolvent in the dissolution media to enhance NIF solubility. HPMCAS-HF was chosen as a 
functional excipient to maintain solubility enhancement, and as a crystallization inhibitor (Tanno 
et al. 2004; Ueda et al. 2013). HPMCAS-HF is known to intercalate with the molecules by 
hydrogen bonding to inhibit the crystallization (Konno Hajime and Taylor Lynne S. 2008).  
SDs are generally prepared by melt or solvent evaporation methods. In this study, a melt solvent 
method was used to prepare the dispersions. The drug-polymer physical mixtures (PMs) and 
their SDs were studied by differential scanning calorimetry (DSC), thermogravimetric analysis 
(TGA), powder X-ray diffraction (PXRD), and Fourier transform infrared spectroscopy (FTIR). 
The drug-polymer dispersions and PMs were stored at controlled conditions (25 ± 2 °C / 60 ± 
5% RH) to study the re-crystallization tendency of the NIF:PEG 1450 and NIF:PEG 
1450:HPMCAS-HF dispersions. 
2. Materials and methods 
NIF (Lot no: YT4QE-OC) was purchased from Tokyo Chemical Industry, Tokyo, Japan. NIF 
reference standard (Lot no.: MKBR1676V) and PEG 1450 (Lot no.: 122K0094) were bought 
from Sigma Aldrich, St. Louis, MO. HPMCAS-AF (Lot no.: 4103177) was obtained as a gift 
from Shin-Etsu Chemical Co. Ltd., Tokyo, Japan. 
2.1. Solubility measurement of NIF 
Approximately 10.00 mg NIF was dissolved in 20 mL of deionized water in a closed flat-
bottomed vial covered with aluminum foil. This solution was subjected to continuous stirring for 
three days at room temperature. The solution was filtered using a Acrodisc
®
 0.45 μ, 13 mm 
nylon membrane syringe filter (PALL Life Sciences, Exton, PA). The NIF concentration in the 
filtrate was analyzed by high performance liquid chromatography (HPLC). Filter absorption 
studies were performed. It was determined that 10 mL of filtrate provided a constant NIF 
concentration. The amount of NIF placed in each vial was in excess of its reported solubility 
value of 5.6 mg/L (Ali and Florey 1989). All analyses were performed in triplicate. 
2.2. HPLC measurements 
Reverse phase HPLC was used to quantify the NIF concentration in solutions. Precision, 
accuracy, selectivity, linearity, and ruggedness were determined by the United States 
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 Pharmacopeia (USP) 40-NF 35 methods (USP 2017). HPLC studies were carried out with an 
Agilent 1100 series system (Agilent Technologies, Santa Clara, CA). A Luna C18 5μ packing 150 
x 4.6 mm column (Phenomenex, Torrance, CA) at 40 °C and NIF reference standard were used 
for analysis. NIF was detected at a wavelength of 236 nm using a UV photodiode array detector. 
The mobile phase was composed of acetonitrile and water in 2:1 v/v. The isocratic elution 
method used a 10.00 µL injection volume, 0.7 mL/min flow rate, and 6 min run time. The elution 
time was 3.5 min. A freshly prepared mobile phase was pumped through the UV-HPLC system 
for 20-30 min prior to each run until a stable baseline was achieved. 
2.3. Preparation of PMs 
Five grams of NIF:PEG 1450 PMs were prepared in ratios of 1:2, 1:4, 1:8, and 1:10 w/w. 
Accurately weighed NIF and PEG 1450 were blended thoroughly via geometric mixing. These 
PMs were stored in amber colored vials. 
2.4. Preparation of NIF SDs 
The SD terminology used throughout the remainder of this research report is described here. 
NIF:PEG 1450 and NIF:PEG 1450:HPMCAS-HF indicates the individual components of the SD. 
In the case where it is important to note the specific NIF and PEG 1450 ratios in the SDs 
(without HPMCAS), the SD’s nomenclature will use NIF:PEG 1450 (specific ratio). To indicate 
the specific ratio of NIF and PEG 1450 for SDs of NIF, PEG 1450 and HPMCAS-HF, the 
nomenclature will be NIF:PEG 1450 (specific ratio):HPMCAS-HF. 
NIF:PEG 1450 SDs were prepared in ratios of 1:2, 1:4, 1:8, and 1:10 w/w with and without 
HPMCAS-HF by the melt solvent method (Vo et al. 2013). A designated amount of PEG 1450 
was weighed in a glass beaker which was heated to 60 °C to melt the polymer. Acetone was used 
to dissolve NIF and HPMCAS-HF. In the case of NIF:PEG 1450 SD, NIF was dissolved in 150 
mL of acetone and was added to previously molten PEG 1450 polymer. The resulting solution 
was mixed at room temperature for 10 min with magnetic stirrer. This solution was transferred to 
a round bottom flask and connected to a rotary evaporator set at 150 bar. The temperature of the 
circulating chiller was set at 0 °C and the water bath was set at 30 °C. The flask was rotated at 30 
rpm and vacuum dried for 15 min. SDs of NIF and PEG 1450 containing 25% w/w HPMCAS-
HF were prepared using the same procedure. Both NIF and HPMCAS-HF were dissolved in 300 
mL of acetone. This solution was then added with stirring to the molten PEG 1450. 
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 2.5. Characterization of NIF, PEG 1450, HPMCAS-HF, their PMs, and SDs 
Individual formulation components (NIF, PEG 1450, and HPMCAS-HF), their PMs, and SDs 
were characterized by differential scanning calorimetry (DSC), thermogravimetric analysis 
(TGA), powder X-ray diffraction (PXRD), and Fourier transform infrared spectroscopy (FTIR). 
2.5.1. DSC/TGA  
Open pan DSC measurements of NIF, PEG 1450, HPMCAS-HF and their PMs were performed 
using a calibrated DSC Q200 (TA instrument, New Castle, DE). Approximately 3 g of sample 
were weighed into an aluminum pan. The samples were heated from a temperature of 20 °C to 
250 °C with an increase of 10 °C/min. The DSC transitions are reported as peak temperatures. 
TGA was carried out using a calibrated TGA Q500 (TA instrument, New Castle, DE). 
Approximately 6 g of sample was weighed into a platinum pan. Samples were heated at a heating 
rate of 10
 
°C/min from 20 °C to 250 °C, depending on the sample material. Nitrogen was purged 
at a flow rate of 40 mL/min for both DSC and TGA. Data was analyzed by using Universal 
Analysis Software
®
 Version 4.5A (TA instrument, New Castle, DE). All experiments were 
performed in triplicate. 
2.5.2. PXRD 
The PXRD studies were performed using a Rigaku Ultima-IV X-ray powder diffractometer 
(Rigaku Amerians, The Woodlands, TX). This diffractometer was equipped with a Bragg-
Brentano geometry (θ/2θ). A scintillation counter was used to monitor the X-ray diffraction. 
Monochromatic CuKβ radiation (λ =1.5406Å) was used at an operating voltage and amperage of 
40 mV and 44 mA, respectively. Samples were mounted evenly as a thin layer on a glass slide. 
Samples were scanned from 5° to 40° 2θ at a rate of 2.00° 2θ/minute. All experiments were 
performed in triplicate.  
2.5.3. Percent crystallinity (PC) 
The PXRD patterns were used to calculate PC. Peaks having full-width-at-half-maximum 
(FWHM) of <5° 2θ were considered crystalline in nature. Peaks having FWHM > 5° 2θ exhibit 
low molecular order regions. The percentage crystallinity was estimated from Equation 1 (Nunes 
et al. 2005; Shah et al. 2006). 
𝐶𝑟𝑦𝑠𝑎𝑙𝑙𝑖𝑛𝑖𝑡𝑦 (%) =
100𝐴𝑐
𝐴𝑐+𝐴𝑎
                (1) 
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 Where, Ac and Aa represents the respective area contributions from the high and low-order 
crystalline phases. Aa also includes amorphous material. The total area underneath the X-ray 
peaks (Ac + Aa) was calculated between 5° to 40° 2θ using the PDXL software version 1.8.03 
(Rigaku Americans, The Woodlands, TX).  
2.5.4  FTIR 
Test material and potassium bromide (KBr) were accurately weighted in the ratio of 1:100 and 
mixed thoroughly in a clean mortar and pestle. This mixture was placed in a KBr pellet die and 
compressed into a transparent pellet. A background scan was performed to remove carbon 
dioxide and water interference from the spectra. A prepared KBr pellet containing sample was 
placed in a sample holder. The spectra was collected using an FTIR spectrophotometer 
(Spectrum One; PerkinElmer®, Waltham, MA) between 4000 to 400 cm
-1
 with a resolution of 4 
cm
-1
. Each individual spectrum was an average of four scans. All experiments were performed in 
triplicate.  
2.5.5  Preliminary physical stability studies 
Preliminary physical stability studies were conducted by storing NIF, PEG 1450, their PMs, and 
SDs with and without HPMCAS-HF in amber colored bottles at controlled temperature and 
humidity conditions. Samples were stored at controlled conditions (25 ± 2 °C / 60 ± 5% RH) for 
5 days. Both solubility and PC were analyzed before and after exposure as mentioned in Sections 
3.1 and 3.5 respectively. Additionally, percent weight loss associated with unexposed SDs were 
measured using TGA thermograms. A first derivative of weight change and temperature was 
used to identify the temperature associated with the maximum rate of water loss in the TGA 
thermograms of SDs.  
2.5.6 Data analysis 
The differences between solubility and PC associated with NIF:PEG 1450 PMs, NIF:PEG SDs 
and, NIF:PEG 1450:HPMCAS-HF SDs were evaluated using JMP
® 
Pro 12.2.0 (SAS Institute, 
Cary, NC). Sample means were compared by Student’s t-test, or one-way analysis of variance 
(ANOVA) followed by Tukey’s Honestly Significant Difference (HSD) post-hoc test, wherever 
applicable. Welch’s ANOVA was used when variances of samples were different during 
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 Student’s t-test analysis. A p-value of less than 0.05 was considered significant. The details of 
statistical interpretation can be found in our previous publication (Gupte et al. 2017). 
3. Results and Discussion 
3.1. Characterization of NIF and SD components 
NIF solubility in water was determined to be 5.52 ± 0.02 μg/mL (Table 1). This solubility value 
is in agreement with the reported literature (Boje et al. 1988; Ali and Florey 1989). Since NIF 
exhibited poor aqueous solubility, NIF SDs were prepared using PEG 1450 in the presence and 
absence of HPMCAS-HF, to study the effect on solubility and physical stability of NIF. NIF 
PMs and SDs solubilities are discussed  in Section 3.5. 
Other molecular level properties of drug and SD components were studied using DSC, TGA, 
PXRD, and FTIR.  
Drug and SD component DSC thermograms are provide in Fig. 2a. NIF showed a single sharp 
melting endotherm at 173.49 ± 0.62 °C compared to the reported value of 171 °C (Friedrich et al. 
2005). PEG 1450 melted at 50.34 ± 0.39 °C. This is in accordance with the reported 50.8 °C 
(Frydrych et al. 2015). The NIF melting endotherm was accompanied by weight loss in the TGA 
thermogram (Fig. 2b), which is most likely due to degradation of NIF upon melting. The PEG 
1450 TGA exhibited two plateau regions. Approximately 0.4% weight loss was recorded from 
25 to 50 °C and additional 0.3% weight loss from 50 to 110 °C. The total weight loss is ascribed 
to surface moisture. The HPMCAS-HF DSC thermogram exhibited a broad endotherm around 
30.86 °C. This endotherm was accompanied by a weight loss in the corresponding TGA. The 
second broad endotherm from 115 to 155 °C is most likely due to a complex set of thermal 
reactions involving HPMCAS-HF’s glass transition temperature at 133 °C (Stroyer et al., 2006) 
and enthalpic relaxation. The third broad endothermic peak starting around 215 °C was 
accompanied by TGA weight loss. This weight loss is attributed to the thermal degradation of 
HPMCAS-HF. 
A NIF PXRD (Fig. 3a) exhibited intense sharp peaks at 8.2°, 10.5°, 11.7°, 16.2°, 24.7°, and 26° 
2θ (Grooff et al. 2007). PEG 1450 (Fig. 3a) revealed two distinct peaks at 19° and 23° 2θ (Bley 
et al. 2010). This confirmed the characteristic crystalline nature of NIF and PEG 1450. It is also 
noted that PEG 1450 has several broad low intensity peaks at 14-15°, 26-27°, and 35-37° 2θ 
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 which have FWHM >5° 2θ suggesting a low molecular order region. The HPMCAS-HF PXRD 
(Fig. 3c) showed a characteristic halo pattern indicating its amorphous nature.  
The N–H group of pure NIF FTIR spectra (Fig. 4aI) display a stretching vibrations at 3332 cm-1. 
In the crystalline state, the N–H group of one NIF molecule forms a hydrogen bond with the 
C=O group of another NIF molecule (Zajc et al. 2005). The stretching vibrations at 3332 cm
-1
 
indicate the crystalline nature of NIF and are sensitive to NIF–NIF intermolecular interactions 
(Iqbal and Chan 2015). NIF–NIF intermolecular hydrogen bonding is further indicated by the 
presence of strong stretching vibrations at 1679 cm
-1
 and 1689 cm
-1
 that are also sensitive to 
intermolecular interactions (Cilurzo et al. 2008). PEG 1450 exhibited –OH and C–H stretching 
vibrations at 3433 cm
-1
 and 2889 cm
-1
, respectively. In addition, it showed C–H bending 
vibrations at 1467 cm
-1
, C–O–C (ether) stretching vibrations at 1280 cm-1, and C–C (ethyl) 
stretching vibrations at 946 cm
-1 
(Frydrych et al. 2015). The HPMCAS-HF displayed several 
characteristic stretching vibrations of –OH at 3488 cm-1, –COCH3 at 1742 cm
-1
, and C=O at 
1121 cm
-1
. Also, it showed –OR1R2 vibrations at 1057 cm
-1
 and 1239cm
-1
. These multiple 
regions serve as a hydrogen bond acceptor sites in HPMCAS-HF (Konno and Taylor 2006; 
Kothari Khushboo et al. 2015). 
3.2. Characterization of PMs of NIF and PEG 1450 
A representative DSC thermogram (Fig. 2a) of NIF: PEG 1450 (1:2) PM showed a sharp melting 
endotherm at 50.69 ± 0.62
 
°C and a broad low enthalpy endotherm at 173. 17
 
± 0.83
 
°C. The 
second broad endotherm disappeared with higher PEG ratios (data not shown). This suggests a 
partial to complete dissolution of NIF in PEG 1450 with increasing amount of polymer. Thus, 
the DSC heating process converts PM into monotectics depending on the amount of polymer 
present in the mixture (Friedrich et al. 2005). 
The PXRD pattern of all PMs (Fig. 3a) displayed sharp crystalline peaks of NIF and PEG 1450. 
However, the height of NIF specific diffraction peaks were reduced and the height of PEG 1450 
specific diffraction peak increased in all PMs with increase in PEG ratio. This can be attributed 
to the change in the fraction of NIF and PEG 1450 present in the various PMs. A statistically 
significant reduction in the PC of the PMs were found with an increase in the PEG 1450 fraction 
(p<0.0001, Fig. 5, Table 1). As stated previously, PEG 1450 contains regions of low molecular 
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 order. As higher ratios of PEG are present in the PM, the crystallinity originating from NIF is 
diluted and the overall PC of the PMs is decreased.  
FTIR spectroscopy (Fig. 4a) was used to examine the intermolecular interactions between NIF 
and the polymers. As mentioned in Section 3.1, the NIF 3332 cm
-1
, 1689 cm
-1
,
 
and 1679 cm
-1
 
bands are sensitive to the NIF–NIF intermolecular hydrogen bonding in the NIF crystalline 
structure. The N–H group of NIF acts as a hydrogen bond donor (Kothari Khushboo et al. 2015) 
and the –OH group of PEG 1450 can participate as a hydrogen bond acceptor. All PMs showed 
NIF characteristic N–H (Fig. 4aI), C=O stretching vibrations (Fig. 4aII), and PEG specific –OH 
stretching vibrations (Fig. 4aI). This indicates that there is no interaction between NIF and PEG 
1450 in their PMs. The observed PM signature peak intensities were lower than pure NIF and 
decreased with each increase in the PEG 1450 fraction. This decrease in intensity with increase 
fraction of PEG 1450 is attributed to the dilution of NIF. 
A PM of NIF:PEG 1450 with HPMCAS-HF were not studied in the present study. This is 
because, our previous study showed that HPMCAS-HF cannot inhibit crystallization after simple 
physical addition (Haware et al. 2015). 
3.3. Characterization of NIF and PEG 1450 SDs 
A PXRD of NIF:PEG 1450 SDs are shown in Fig. 3b. As the PEG 1450 ratio increased, the 
characteristic NIF and PEG 1450 PXRD peaks decreased indicating a decrease in the 
crystallinity of both materials resulting in a lower-order SD. The PC of unexposed SDs can be 
arranged in the following descending order: SD NIF:PEG 1450 (1:2) > SD NIF:PEG 1450 (1:4) 
> SD NIF:PEG 1450 (1:10) > SD NIF:PEG 1450 (1:8) (Table 1). These differences in the 
crystallinity are statistically significant (p<0.0001, Fig. 5).  
FTIR spectroscopy (Fig. 4b) showed intermolecular hydrogen bonding between the NIF N–H 
group and PEG 1450 –OH group. In Fig. 4bI, the 1:8 and 1:10 NIF:PEG 1450 ratios show a 
significant band broadening and shift from 3332 cm
-1
 to 3412 cm
-1
. Band broadening generally 
results from individual molecules hydrogen bonding to different extents. The band shift to higher 
wavenumbers indicates the PEG 1450:NIF hydrogen bond is weaker than the NIF:NIF 
intermolecular hydrogen bonds (Nie et al. 2005; Kothari K. et al. 2015). The disruption of the 
intermolecular NIF–NIF hydrogen bonds creates a lower-ordered NIF. This peak broadening and 
shift is less obvious at lower PEG 1450 ratios. Fig. 4bII further supports the observed reduction 
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 in the order of pure crystalline NIF with the band merging of the 1679 cm
-1
 and 1689 cm
-1
 C=O 
group bands and a shift for the merged band to higher wave numbers (Iqbal and Chan 2015). 
 
In 
case of the more disordered SDs such as NIF:PEG 1450 (1:8) and NIF:PEG 1450 (1:10), the 
C=O specific 1679 cm
-1
 and 1689 cm
-1
 bands were merged into a single band and it was shifted 
to 1700 cm
-1
 (Fig. 4bII). On the other hand, the relatively higher ordered SDs like SD NIF:PEG 
1450 (1:2) and SD NIF:PEG 1450 (1:4) showed two separate C=O specific bands like pure NIF. 
These FTIR findings corroborate the results of the PXRD studies, which shows increasing the 
PEG 1450 ratio produces lower-order SD matrices. Thus, hydrogen bonding is clearly involved 
in the amorphization process. However, the C=O specific bands were shifted to higher 
wavelengths, indicating weaker bonding between NIF and PEG 1450 compared to NIF:NIF 
bonding. Thus, it is posited that the extent of NIF:PEG 1450 interaction does not lead  to 
complete SD amorphization.  
3.4. Characterization of NIF:PEG 1450:HPMCAS-HF SDs 
Fig. 4c presents the FTIR data for the NIF:PEG 1450:HPMCAS-HF SDs. Fig. 4cI shows similar 
band broadening and shifting of the 3332 cm
-1
 band noted for the NIF:PEG 1450 SDs (3332 cm
-1
 
to 3412 cm
-1
, Fig. 4bI). The band shift for the NIF:PEG 1450:HPMCAS-HF SDs was from 3332 
cm
-1
 to 3455 cm
-1 
(Fig. 4cI). The NIF:PEG 1450:HPMCAS-HF SD hydrogen bonding band at 
3455 cm
-1 
is a higher wavenumber than the NIF:PEG 1450 SD 3412 cm
-1
 band. This indicates 
that hydrogen bond of the HPMCAS-HF containing SD’s is weaker than the NIF:PEG 1450 SDs. 
The observed hydrogen bonding between NIF and HPMCAS-HF is corroborated by the research 
of Konno and Taylor which demonstrated that NIF intercalates with HPMCAS by hydrogen 
bonding (Konno H. and Taylor L. S. 2008). It was also found that unlike SDs without a 
crystallization inhibitor, C=O group specific 1679 cm
-1
 and 1689 cm
-1
 bands were not merged 
into a single band (Fig. 4cII and Fig. 4cIII). Rather, these SDs exhibited a low intensity doublet 
bands at 1682 cm
-1 
and 1685 cm
-1
 (Fig. 4cIII). Another broad band is seen at 1700 cm
-1
 (Fig. 4cII 
and 4cIII). The 1700 cm
-1
 band has higher absorbance than the 1682 cm
-1 
and 1685 cm
-1
 bands. 
The 1702 cm
-1
 and 1682 cm
-1 
bands have been assigned previously by Konno and Taylor to non-
hydrogen bonded and hydrogen bonded carbonyl groups in the felodipine, which is a structural 
analog of NIF (Konno and Taylor 2006). In the case of NIF, the 1700 cm
-1
 band demonstrated 
greater absorbance than the 1682 cm
-1 
and 1865 cm
-1
 bands. The greater absorbance of the 1700 
cm
-1
 non-hydrogen bonding band relative to the 1682 cm
-1 
hydrogen bonding
 
band strongly 
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 suggests that hydrogen bonding between C=O group of NIF and –OH group of PEG 1450 was 
weakened in the presence of HPMCAS-HF. This is consistent with the observed NIF:PEG 
1450:HPMCAS-HF SD 3332 cm
-1
 band shift to a higher wavenumber, indicating a weaker NIF 
interaction compared to NIF:PEG 1450. Interestingly, the band at 1746 cm
-1
 was found in the 
NIF:PEG 1450:HPMCAS-HF SDs (Fig. 4cII). This band is specific to the –COCH3 group of 
HPMCAS-HF. It is conjectured that the –COCH3 group does not undergo a significant level of 
hydrogen bonding with NIF in the presence of PEG 1450. Kothari et al. also observed a similar 
trend in NIF:PVP SDs prepared in the presence of HPMCAS (Kothari Khushboo et al. 2015). In 
this study, the addtion of HPMCAS-HF to the dispersion tended to result in overall weaker 
hydrogen bonding interactions with NIF. 
3.5. Preliminary physical stability studies  
Statistical analysis of the solubility and PC data for the PMs, and SDs with and without 
HPMCAS-HF were compared by Student t-test and one-way ANOVA for unexposed day 0 and 
exposed controlled conditions after 5 days. Additionally, statistical analysis of weight loss 
associated with water uptake of unexposed SDs with and without HPMCAS-HF measured by 
TGA was performed. 
The solubility comparisons of PMs and SDs are provided in Fig. 6. The one-way ANOVA 
indicated that the solubility of NIF in PMs, NIF:PEG 1450 SDs, and NIF:PEG 1450:HPMCAS-
HF SDs were statistically different (p<0.0001, Fig. 6, Table 1). The Tukey’s HSD post-hoc 
analysis showed an increase in NIF solubility with an increase in PEG 1450 fractions in the PMs 
(p<0.0001-0.0020). The NIF:PEG 1450 SDs demonstrated a statistically significant solubility 
increase compared to their PM counterparts (p<0.0001). This increase in solubility resulted from 
the amorphization of NIF to lower-order higher-energy SD matrices. Furthermore, NIF:PEG 
1450:HPMCAS-HF SDs provided significantly greater NIF solubility than NIF:PEG 1450 SDs 
(p<0.0001-0.0403). This solubility increase can be attributed to HPMCAS-HF SDs ability to 
inhibit nucleation and crystallization in the dissolution media (Konno and Taylor 2006; Konno 
Hajime and Taylor Lynne S. 2008). The Student t-test demonstrated a significant decrease in the 
solubility of the PMs and SDs with and without HPMCAS-HF, when stored at the controlled 
conditions for five days (p<0.0001). Neither the NIF:PEG 1450 SDs nor NIF:PEG 
1450:HPMCAS-HF SDs sufficiently inhibit NIF crystallization when exposed to 60% RH for 5 
days. After careful review of the data, the authors do not have an explanation for the reduction in 
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 the NIF solubility in the PMs at the controlled conditions. Although HPMCAS-HF enhanced NIF 
solubility to a greater extent than NIF:PEG 1450 SD alone, it did not enhance the physical 
stability of the SD. Therefore, the working hypothesis stating that HPMCAS-HF would provide 
enhanced solubility and physical stability (minimize recrystallization) compared to a NIF:PEG 
1450 SD alone was rejected.  
The PC of the various matrices are plotted in Fig. 5. The SDs displayed a decrease in PC 
compared to the PMs. The melt solvent amorphization technique was shown to be a viable 
process to create low-order high-energy materials. The one-way ANOVA indicated statistically 
significant differences in the PCs of unexposed day 0 NIF, NIF:PEG 1450, and NIF:PEG 
1450:HPMCAS-HF (p < 0.0001, Fig. 5). Post-hoc analysis showed the PC differences between 
PM (1:10) and SD NIF:PEG 1450 (1:2) were statistically insignificant (p>0.05). The Student t-
test demonstrated a significant increase in the crystallinity of PM, NIF:PEG 1450 SDs, and 
NIF:PEG 1450:HPMCAS-HF SDs stored at the controlled storage conditions for five days 
(p<0.0001-0.0089). The PC increase of the PMs after the 5 days storage period suggests that the 
low-order regions of PEG 1450 are crystallizing upon exposure to moisture at 60% RH. It was 
surprising that HPMCAS-HF did not inhibit crystallization since it has been shown to intercalate 
with NIF.  
The percent weight loss, associated with water uptake of unexposed SDs on Day 0, at and below 
100 
o
C, above 100
 o
C, and total weight loss consisting both below and above 100
 o
C is given in 
Table 2. The weight loss associated with SD 1:10 with HPMCAS-HF was obtained with two 
measurements and thus, it was not included in the statistical analysis. The one-way ANOVA 
indicated statistically significant differences in the percent weight loss of all unexposed SDs with 
and without HPMCAS-HF measured at and below 100 
o
C, above 100
 o
C, and total weight loss 
consisting both below and above 100
 o
C (p < 0.0001). The percent weight loss of SDs with and 
without HPMCAS-HF, having the same ratio of drug and polymer, were compared using the 
Tukey-Kremer HSD test. This statistical test showed significant differences measured at and 
below 100 
o
C, and above 100
 o
C (p < 0.0001-0.0039). Highly disordered SDs seems to sorb 
moisture from Day 0. The majority of weight loss associated with SDs in absence of HPMCAS-
HF (between 94 to 99 % w/w of total weight loss) was observed below 100
 o
C. In contrast to this, 
higher weight loss associated with SDs in presence of HPMCAS-HF was observed above 100
 o
C 
(between 50% to 69 % w/w of total weight loss). Clearly, the water sorbed by SDs in the absence 
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 of HPMCAS-HF seems less tightly bound than in presence of HPMCAS-HF. This can be 
attributed to the higher affinity of hydrophilic HPMCAS-HF towards water (Konno Hajime and 
Taylor Lynne S. 2008). In the absence of HPMCAS-HF, the less tightly bound water may 
increase the overall molecular mobility of disordered SDs. This increase in molcular mobility is 
thought to result in an increase in their PC (Hancock and Zografi 1997; Haware et al. 2015). 
However, HPMCAS-HF’s ability to more tightly bind water and NIF:HPMCAS-HF bonding 
appears to be responsible for slowing down the crystallization of SDs. Therefore, PC of SDs 
containing HPMCAS-HF was significantly lower than SDs prepared without it. 
4. Conclusions 
The melt solvent amorphization technique using PEG 1450 and HPMCAS-HF was shown to be a 
viable process to create low-order high-energy NIF SDs. FTIR results showed that 
NIF:HPMCAS-HF intermolecular interactions were found to be weaker than NIF:PEG 1450 
interactions.  
The SDs of NIF with PEG 1450 prepared by the melt solvent method significantly improved NIF 
solubility (p<0.0001) due to amorphization of NIF. This solubility was further enhanced by the 
addition HPMCAS-HF compared to NIF:PEG 1450 SDs (p<0.0001-0.0403). A significant 
decrease in the solubility of the NIF:PEG 1450 SDs and NIF:PEG 1450:HPMCAS-HF SDs was 
found after storage at the controlled conditions for five days (p<0.0001). 
The prepared SDs displayed a statistically significant decrease in PC compared to their PM 
counterparts (p<0.0001) as a result of creating lower-ordered higher-energy dispersed system 
matrices. The PCs of SDs with HPMCAS-HF were significantly lower than SDs not containing 
HPMCAS-HF. This is attributed to NIF:HPMCAS-HF bonding and the tight bonding between 
water and hydrophilic HPMCAS-HF which may reduce the overall molecular mobility of the 
disordered SDs. All SDs stored at controlled conditions for five days exhibited a significant 
increase in PC (p<0.0001-0.0089). 
The results of the present study revealed that although HPMCAS-HF improves the solubility of 
NIF, it does not provide crystal growth inhibition of NIF:PEG 1450:HPMCAS-HF SDs.   
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Figure 1 Structure of nifedipine 
Figure 2: Open pan differential scanning calorimetry of NIF, PEG 1450, HPMCAS-HF, and 
physical mixture (PM) of NIF:PEG (1:2). [b] Thermogravimetric analysis of NIF, PEG 1450, 
and HPMCAS-HF. 
Figure 3. Powder x-ray diffraction pattern of [a] NIF, PEG 1450, and their PM, [b] NIF:PEG 
1450 solid dispersions (SD), and [c] NIF:PEG 1450:HPMCAS-HF SDs. 
Figure 4. Fourier transform infrared spectra of [a] NIF, PEG 1450, and their PM, [b] 
NIF:PEG 1450 (1:2, 1:4, 1:8, and 1:10) SD [c] NIF:PEG 1450 (1:2, 1:4, 1:8, and 1:10: plus 
HPMCAS-HF) SD . (I) 3332 cm
-1
 spectra; (II) 1689 cm
-1
 and 1679 cm
-1
 spectra; (III) 1701
cm
-1
 and 1682 cm
-1
 spectra.
Figure 5. Percent crystallinity comparison of NIF, PM of NIF and PEG 1450, SD of NIF and 
PEG 1450 with and without HPMCAS-HF in different ratios exposed at different time 
intervals. [n=3; Each error bar is constructed using a 95% confidence interval of the mean.] 
Figure 6. Solubility comparison of PM of NIF and PEG 1450, SD of NIF and PEG 1450 
with and without HPMCAS-HF in different ratios exposed at different time intervals. [n=3; 
Each error bar is constructed using a 95% confidence interval of the mean.] 
Table 1 NIF solubility (μg/mL) and percent crystallinity (%) in PM and SD 
Table 2 Percent weight loss associated water content of solid dispersions measured by 
thermogravimetric analysis at Day 0 
Figure 1 Structure of nifedipine 
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Figure 2. [a] Open pan differential scanning calorimetry of NIF, PEG 1450, HPMCAS-HF, and 
physical mixture (PM) of NIF:PEG (1:2). [b] Thermogravimetric analysis of NIF, PEG 1450, 
and HPMCAS-HF. 
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Figure 3. Powder x-ray diffraction pattern of [a] NIF, PEG 1450, and their PM, [b] NIF:PEG 
1450 solid dispersions (SD), and [c] NIF:PEG 1450:HPMCAS-HF SDs.  
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Figure 4. Fourier transform infrared spectra of [a] NIF, PEG 1450, and PMs [b] NIF:PEG 1450 
(1:2, 1:4, 1:8, and 1:10) SDs [c] NIF:PEG 1450 (1:2, 1:4, 1:8, and 1:10: plus HPMCAS-HF) 
SDs.. (I) 3332 cm
-1
 spectra; (II) 1689 cm
-1
 and 1679 cm
-1
 spectra; (III) 1701 cm
-1
 and 1682 cm
-1
 
spectra. 
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Figure 5. Percent crystallinity comparison of NIF, PM of NIF and PEG 1450, SD of NIF and 
PEG 1450 with and without HPMCAS-HF in different ratios exposed at different time intervals. 
[n=3; Each error bar is constructed using a 95% confidence interval of the mean.] 
 
 
 
Figure 6. Solubility comparison of PM of NIF and PEG 1450, SD of NIF and PEG 1450 with 
and without HPMCAS-HF in different ratios exposed at different time intervals. [n=3; Each error 
bar is constructed using a 95% confidence interval of the mean.] 
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Table 1 NIF solubility (μg/mL) and percent crystallinity (%) in PM and SD 
Components/Formulations 
NIF solubility (μg/mL)a Percent crystallinity (%) 
0 day 
5 days 
(25 °C /60% RH) 
0 day 
5 days 
(25 °C /60% RH) 
NIF 5.52 ± 0.02 2.22 ± 0.05 98.28 ± 0.28 99.91 ± 0.06 
PM NIF:PEG (1:2) 5.00 ± 0.00 0.97 ± 0.00 83.66 ± 1.41 87.74 ± 0.45 
PM NIF:PEG (1:4) 5.35 ± 0.01 1.48 ± 0.01 81.09 ± 0.61 84.15 ± 0.12 
PM NIF:PEG (1:8) 5.51 ± 0.00 2.00 ± 0.02 77.01 ± 0.62 81.52 ± 0.91 
PM NIF:PEG (1:10) 6.73 ± 0.03 2.71 ± 0.02 72.84 ± 0.25 79.72 ± 0.08 
SD NIF:PEG (1:2) 7.97 ± 0.13 4.93 ± 0.03 72.91 ± 0.12 77.89 ± 0.04 
SD NIF:PEG (1:4) 9.16 ± 0.01 4.10 ± 0.00 58.36 ± 0.36 60.58 ± 0.21 
SD NIF:PEG (1:8) 13.31 ± 0.01 5.02 ± 0.01 26.50 ± 0.20 40.76 ± 0.58 
SD NIF:PEG (1:10) 12.75 ± 0.03 5.08 ± 0.03 28.28 ± 0.27 37.94 ± 0.09 
SD NIF:PEG (1:2) + HPMCAS-HF 8.09 ± 0.00 5.34 ± 0.02 30.87 ± 0.19 44.32 ± 1.46 
SD NIF:PEG (1:4) + HPMCAS-HF 10.10 ± 0.01 5.86 ± 0.01 26.70 ± 0.22 39.74 ± 0.15 
SD NIF:PEG (1:8) + HPMCAS-HF 14.59 ± 0.01 6.08 ± 0.02 23.16 ± 0.24 36.65 ± 0.07 
SD NIF:PEG (1:10) + HPMCAS-HF 22.02 ± 0.02 7.24 ± 0.04 15.37 ± 0.26 23.80 ± 0.18 
a
mean ± standard deviation; n=3. 
Table 2: Percent weight loss associated water content of solid dispersions measured by 
thermogravimetric analysis at Day 0 
Sample name 
First Weight 
Loss <100 
o
C
(%) 
Second Weight 
Loss >110 
o
C
(%)  
Total Weight 
Loss (%) 
SD NIF:PEG (1:2) 10.154 (0.735) 0.573 (0.717) 10.727 (1.251) 
SD NIF:PEG (1:4) 10.178 (1.509) 0.165 (0.083) 10.344 (1.493) 
SD NIF:PEG (1:8) 17.664 (2.507) 0.215 (0.112) 17.879 (2.546) 
SD NIF:PEG (1:10) 13.151 (3.063) 0.111 (0.044) 13.262 (3.019) 
SD NIF:PEG (1:2)+HPMCAS-HF 2.975 (0.558) 3.063 (0.639) 6.038 (0.693) 
SD NIF:PEG (1:4)+HPMCAS-HF 3.091 (0.567) 8.672 (2.223) 11.763 (2.320) 
SD NIF:PEG (1:8)+HPMCAS-HF 5.400 (3.011) 10.727 (4.305) 16.127 (7.219) 
SD NIF:PEG (1:10)+HPMCAS-HF 5.145* (0.179) 11.970* (0.721) 17.115* (0.542) 
[n=3; Values in parenthesis indicates standard deviation; * indicated average of two measurements] 
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